New York-listed Regeneron secures $270 million US Ebola order as African outbreak approaches 10,000 infections
US pharmaceutical company Regeneron has secured an additional $270 million order from the US government for its approved Ebola treatment as a separate strain of the virus spreads across Africa.
By Ayodeji AdegboyegaSouth Africa
AI summary
Sign in to read the summary
Regeneron will receive approximately $270 million for additional supplies of its approved Ebola treatment, Inmazeb. [Regeneron ]
Follow the story
About this article
- Length
- 17 words · 1 min read
- Published
- October 28, 2026
- Byline
- Ayodeji Adegboyega
- Source
- Business Insider